Advanced Enzyme Technologies Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹2,959 Cr
- P/E
- 18.76
- ROE
- 10.16%
- PEG
- 1.49
- Price to sales
- 3.96
- Debt to equity
- 0.02
- 52W high / low
- ₹392 / ₹248
- Sales growth (5Y)
- 8.24%
- EBITDA margin
- 29.83%
- Net profit margin
- 21.39%
- Promoter holding
- 43.56%
- Sales (last year)
- ₹750 Cr
Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.[1]
Guidance scorecard · Q1 FY27 call
What Advanced Enzyme Technologies Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
10–20%- The company expects to achieve double-digit growth in the coming quarters despite some sales reversals affecting recent results.
- Growth in the U.S. market is projected at around 8-10%, driven by branding efforts and gradual strategic changes rather than immediate product launches.
- The business model focuses on sustained growth with a steady customer base, with 70-80% customers being consistent and 20-30% changing.
- Growth is expected to come from a combination of new and existing products across various segments.
- Biocatalysis is considered a high-growth segment, with good growth anticipated particularly in the second half of the year.
2 more points from Advanced Enzyme Technologies Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Advanced Enzyme Technologies Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- The company plans a total CapEx of INR 123 crore as discussed in the AGM.
- Approximately INR 20 crore is for normal capital expenditure, INR 50 crore will be for R&D (work in progress), and the remaining is for growth.
- The CapEx is expected to span FY27, with about INR 20 crore possibly extending into Q2 FY27.
- Current fermentation capacity utilization is around 70-75%, prompting potential capacity expansion.
- Plans to increase capacity will be taken up in the next quarter.
2 more points from Advanced Enzyme Technologies Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Advanced Enzyme Technologies Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
Rising- Mukund Kabra mentions variability of 20-30% in customers quarter-on-quarter, indicating some order fluctuation.
- There’s mention of some inventory and order-related delays or complexities at the customer level.
- Mukund Kabra signals optimism about a "robust pipeline of sales orders" going forward.
2 more points from Advanced Enzyme Technologies Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Advanced Enzyme Technologies Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Advanced Enzyme Technologies Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Advanced Enzyme Technologies Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 139 | 147 | 158 | 161 | 158 | 155 | 146 | 169 | 167 | 186 | 185 | 172 | 203 |
| Expenses + | 95 | 103 | 107 | 107 | 102 | 103 | 104 | 114 | 122 | 129 | 124 | 123 | 140 |
| Operating Profit | 44 | 44 | 51 | 54 | 55 | 51 | 42 | 55 | 46 | 56 | 60 | 49 | 63 |
| OPM % | 32% | 30% | 32% | 33% | 35% | 33% | 29% | 33% | 27% | 30% | 33% | 29% | 31% |
| Other Income + | 7 | 7 | 6 | 14 | -6 | 7 | 10 | 8 | 9 | 9 | 10 | 20 | 7 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 |
| Profit before tax | 42 | 41 | 48 | 59 | 40 | 49 | 42 | 53 | 43 | 55 | 60 | 58 | 60 |
| Tax % | 24% | 29% | 27% | 28% | 25% | 28% | 21% | 27% | 38% | 26% | 25% | 26% | 24% |
| Net Profit + | 32 | 29 | 35 | 42 | 30 | 35 | 33 | 39 | 27 | 40 | 45 | 43 | 45 |
| EPS in Rs | 2.87 | 2.58 | 3.08 | 3.74 | 2.53 | 3.05 | 2.94 | 3.37 | 2.37 | 3.57 | 3.87 | 3.80 | 3.84 |
Financials of Advanced Enzyme Technologies Ltd
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 222 | 293 | 329 | 391 | 420 | 444 | 502 | 529 | 541 | 624 | 637 | 746 |
| Expenses + | 131 | 155 | 177 | 226 | 236 | 241 | 269 | 327 | 382 | 418 | 441 | 517 |
| Operating Profit | 91 | 138 | 152 | 165 | 184 | 203 | 232 | 203 | 158 | 206 | 196 | 229 |
| OPM % | 41% | 47% | 46% | 42% | 44% | 46% | 46% | 38% | 29% | 33% | 31% | 31% |
| Other Income + | 1 | -3 | 3 | 1 | 5 | 6 | 9 | 6 | 21 | 21 | 33 | 46 |
| Interest | 9 | 8 | 4 | 9 | 5 | 4 | 3 | 3 | 3 | 4 | 5 | 3 |
| Depreciation | 9 | 9 | 13 | 18 | 21 | 26 | 28 | 35 | 35 | 35 | 37 | 40 |
| Profit before tax | 74 | 118 | 137 | 139 | 162 | 179 | 210 | 171 | 140 | 188 | 187 | 233 |
| Tax % | 31% | 35% | 32% | 33% | 28% | 26% | 28% | 28% | 26% | 27% | 28% | 25% |
| Net Profit + | 51 | 77 | 93 | 94 | 116 | 133 | 151 | 124 | 104 | 137 | 134 | 174 |
| EPS in Rs | 4.60 | 6.97 | 8.20 | 8.07 | 9.95 | 11.58 | 13.09 | 10.70 | 9.45 | 11.92 | 11.72 | 15.07 |
| Dividend Payout % | 4% | 3% | 5% | 6% | 6% | 5% | 7% | 9% | 11% | 43% | 44% | 9% |
Financials of Advanced Enzyme Technologies Ltd
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| Reserves | 188 | 256 | 442 | 537 | 657 | 817 | 948 | 1,066 | 1,213 | 1,302 | 1,398 | 1,610 |
| Borrowings + | 115 | 101 | 54 | 67 | 35 | 28 | 23 | 35 | 34 | 47 | 39 | 32 |
| Other Liabilities + | 92 | 71 | 65 | 102 | 91 | 104 | 153 | 137 | 142 | 150 | 151 | 175 |
| Total Liabilities | 417 | 450 | 583 | 727 | 805 | 971 | 1,146 | 1,260 | 1,411 | 1,521 | 1,611 | 1,839 |
| Fixed Assets + | 287 | 285 | 421 | 491 | 495 | 563 | 601 | 619 | 649 | 650 | 679 | 692 |
| CWIP | 5 | 7 | 8 | 11 | 10 | 10 | 10 | 15 | 22 | 41 | 22 | 51 |
| Investments | 0 | 0 | 0 | 0 | 111 | 124 | 121 | 102 | 360 | 403 | 480 | 584 |
| Other Assets + | 125 | 158 | 153 | 226 | 188 | 275 | 413 | 524 | 380 | 427 | 430 | 511 |
| Total Assets | 417 | 450 | 583 | 727 | 805 | 971 | 1,146 | 1,260 | 1,411 | 1,521 | 1,611 | 1,839 |
Financials of Advanced Enzyme Technologies Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 54 | 93 | 107 | 116 | 129 | 141 | 163 | 122 | 140 | 141 | 142 | 157 |
| Cash from Investing Activity + | -15 | -10 | -60 | -60 | -124 | -43 | -27 | 2 | -286 | -65 | -89 | -74 |
| Cash from Financing Activity + | -36 | -63 | -65 | -2 | -43 | -39 | -26 | -48 | -26 | -59 | -73 | -70 |
| Net Cash Flow | 2 | 21 | -18 | 54 | -38 | 60 | 109 | 75 | -171 | 17 | -20 | 12 |
| Free Cash Flow | 42 | 88 | 97 | 105 | 116 | 90 | 143 | 95 | 102 | 94 | 108 | 105 |
| CFO/OP | 88% | 88% | 105% | 97% | 70% | 69% | 94% | 87% | 112% | 93% | 103% | 97% |
Financials of Advanced Enzyme Technologies Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 52 | 55 | 55 | 51 | 61 | 63 | 61 | 68 | 58 | 66 | 71 |
| Inventory Days | 403 | 358 | 352 | 339 | 363 | 361 | 346 | 402 | 343 | 375 | 378 | 335 |
| Days Payable | 89 | 68 | 57 | 78 | 46 | 43 | 56 | 60 | 67 | 40 | 41 | 76 |
| Cash Conversion Cycle | 374 | 342 | 351 | 315 | 369 | 379 | 353 | 404 | 344 | 393 | 403 | 331 |
| Working Capital Days | -43 | 3 | 76 | 47 | 72 | 90 | 94 | 116 | 109 | 102 | 112 | 402 |
| ROCE % | 25% | 36% | 31% | 25% | 24% | 22% | 22% | 16% | 12% | 15% | 13% | 14% |
Guidance history
How Advanced Enzyme Technologies Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 10–20% | Flat | Planned | — | Rising |
| Q4 FY26 call → | 10–20% | Flat | Planned | — | Rising |
| Q3 FY26 call → | 10–20% | Flat | Planned | — | — |
| Q2 FY26 call → | 10–20% | Flat | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
14 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −14.6% | 43% |
| Last 6 months | −24.0% | 13% |
| Last 3 months | −13.7% | 31% |
The price is 50.9% below its all-time high of ₹538.05 (20 Sept 2024). Stocks more than 20% below their peak have their score halved, so 29 became 14.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Advanced Enzyme Technologies Ltd: 0.4 × 43 + 0.4 × 13 + 0.2 × 31 = 29, halved to 14 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Advanced Enzyme Technologies Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY